EICHORPublic-registry site landscape for NCT06514742, “A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant”, a Depressive Disorder, Major study sponsored by Janssen Research & Development, LLC. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06514742 (registry record) |
| Study title | A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant |
| Official title | A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open Label Long-term Extension Treatment With Aticaprant |
| Sponsor | Janssen Research & Development, LLC |
| Condition(s) | Depressive Disorder, Major; Anhedonia |
| Phase | PHASE3 |
| Listed sites | 84 |
| Site countries | United States, Belgium, Brazil, Bulgaria, Finland, Hungary, Poland, Spain, Sweden |
Patient-friendly overview of this study: eichor.com/study/NCT06514742.
Eichor generates a preliminary site-risk snapshot for NCT06514742 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Depressive Disorder, Major trials
More from Janssen Research & Development, LLC
← Eichor home · All tracked trials · Depressive Disorder, Major studies · Weekly briefs
